Document is current
Any future updates will be listed below
-
Authors
Nakakana, Usman https://orcid.org/0000-0002-4885-9485
Serry-Bangura, Alimamy https://orcid.org/0000-0002-8937-8346
Edem, Bassey Effiom https://orcid.org/0000-0002-9783-1542
Tessitore, Pietro https://orcid.org/0000-0002-4181-0929
Di Cesare, Leonardo https://orcid.org/0000-0003-3928-9852
Moriel, Danilo Gomes https://orcid.org/0000-0002-1421-8129
Podda, Audino https://orcid.org/0000-0002-1340-4982
De Ryck, Iris Sarah https://orcid.org/0000-0003-3044-1117
Arora, Ashwani Kumar
- License Information
-
More Information
Article History
Accepted: 7 January 2024
First Online: 18 March 2024
Declarations
:
: StreptAvax is a trademark of ID Biomedical. StreptAnova is a trademark of Dalhousie University.
: This work was supported by GlaxoSmithKline Biologicals SA. GlaxoSmithKline Biologicals SA was involved in all stages of the conduct and analysis of the studies and covered the costs associated with the development and publishing of the present article.
: Usman Nakakana, Alimamy Serry-Bangura, Bassey Effiom Edem, Pietro Tessitore, Leonardo Di Cesare, Danilo Gomes Moriel, Audino Podda, Iris Sarah De Ryck and Ashwani Kumar Arora are or were employees of GSK at the time of this study. Usman Nakakana, Alimamy Serry-Bangura, Danilo Gomes Moriel, Audino Podda, Iris Sarah De Ryck and Ashwani Kumar Arora hold shares in GSK. GSK is currently developing a 4-component vaccine candidate against <i>S. pyogenes.</i>
: Not applicable.
: Not applicable.
: Not applicable.
: Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
: Not applicable.
: All authors contributed to the interpretation of the data and a critical review of the paper for important intellectual content. All authors read and approved the final manuscript.
